Flag of the European Union EU Clinical Trials Register Help

Clinical trials for L1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    199 result(s) found for: L1. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000164-24 Sponsor Protocol Number: 109836 Start Date*: 2007-05-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, partially-blind, randomized multicentre study to assess the safety and immunogenicity of an HPV-16/18/33/58 L1 VLP vaccine formulated with different adjuvant systems when administered...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000108-42 Sponsor Protocol Number: V505-001 Start Date*: 2017-01-27
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase IIa Randomized, Double-Blinded, Controlled With GARDASIL™ Clinical Trial to Study the Tolerability and Immunogenicity of V505 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like-Particl...
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000109-19 Sponsor Protocol Number: V502-001 Start Date*: 2017-01-27
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58...
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003486-17 Sponsor Protocol Number: 9-VPH-MVIH Start Date*: 2020-02-11
    Sponsor Name:CARMEN HIDALGO TENORIO
    Full Title: Immunogenicity and safety of a 9-valent human papillomavirus vaccine in HIV-positive women
    Medical condition: New infection and lesions of papillomavirus in HIV-infected women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000215-24 Sponsor Protocol Number: GeSIDA10017 Start Date*: 2018-06-05
    Sponsor Name:Fundacion SEIMC-GESIDA
    Full Title: A single-arm, open-label and multicentre phase IV trial to evaluate the immunogenicity of the nonavalent vaccine against human papillomavirus in HIV-infected men who have sex with men. GESIDA 10017...
    Medical condition: AIDS
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000333-13 Sponsor Protocol Number: APHP200046 Start Date*: Information not available in EudraCT
    Sponsor Name:APHP DRCI
    Full Title: Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts
    Medical condition: Vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts in patients of more than 15 years and 3 months of age
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023393-39 Sponsor Protocol Number: GDS01C Start Date*: 2011-01-13
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A Randomized, Double-Blinded, Controlled with GARDASIL® (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Toler...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066416 Vulvovaginal human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: FI (Completed) BE (Completed) SE (Completed) ES (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003399-10 Sponsor Protocol Number: GDS07C Start Date*: 2014-03-24
    Sponsor Name:Sanofi Pasteur MSD S.N.C.
    Full Title: A Randomized, Double-Blinded, Controlled with GARDASIL® (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerabi...
    Medical condition: Prevention of premalignant genital lesions (cervical, vulvar and vaginal) and cervical cancer and genital warts (condyloma acuminata) causally related to Human Papillomavirus (HPV) Types 6, 11, 16,...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10061331 Papilloma viral infection PT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000228-33 Sponsor Protocol Number: CE/17-12-06 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU Saint-Pierre
    Full Title: Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women
    Medical condition: Immune responses to administration of 9valent vaccine against HPV in HIV-positive women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10020180 HIV positive LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005093-38 Sponsor Protocol Number: V503-004 Start Date*: 2016-07-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc
    Full Title: An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27-...
    Medical condition: Prevention of cervical,vulvar,vaginal, and anal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by HPV Types 6,11,16,18,31,33,45,52,58
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061331 Papilloma viral infection PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) FI (Completed) AT (Completed) ES (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003591-13 Sponsor Protocol Number: V503-076 Start Date*: 2024-05-06
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Conco...
    Medical condition: Papilloma viral infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-003177-42 Sponsor Protocol Number: COHEAHR-WP4 Start Date*: 2014-10-10
    Sponsor Name:Catalan Institute of Oncology
    Full Title: Multinational study assessing the acceptability and determinants of compliance to HPV vaccination to women in screening ages 30 to 45 years
    Medical condition: Cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10008229 Cervical cancer LLT
    19.0 100000004872 10056576 Cervical intraepithelial neoplasia LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed) ES (Completed) BE (Completed) FI (Completed) SI (Completed) NL (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003528-39 Sponsor Protocol Number: V503-001 Start Date*: 2007-11-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavi...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004581-16 Sponsor Protocol Number: V501-030 Start Date*: 2015-04-02
    Sponsor Name:Merck Sharp & Dohme (China) Ltd.
    Full Title: An Immunogenicity and Safety Study of GARDASIL™ in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years
    Medical condition: Prevention of HPV types 6, 11, 16 and 18 related cervical cancer, vulvar, vaginal pre-cancers, low-grade, pre-cancerous lesions, and genital warts in Chinese female subjects aged 9 to 45 years and ...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000111-16 Sponsor Protocol Number: V501-029 Start Date*: 2017-01-11
    Sponsor Name:Merck & Co., Inc.
    Full Title: Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in healthy females 9 to 15 years of age in India.
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-007876-41 Sponsor Protocol Number: 111567 Start Date*: 2008-03-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, randomized, open study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) when co-administered with GlaxoSmithKline Biologicals...
    Medical condition: Cervarix™ is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002777-32 Sponsor Protocol Number: 110659 Start Date*: 2007-10-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, partially blind, randomized, multicentre, age-stratified, dose-range study in healthy females aged 9 - 25 years to assess the safety and immunogenicity of GlaxoSmithKline Biologicals’...
    Medical condition: For active immunization of females for the prevention of cervical cancer by protecting against persistent infections, cytological abnormalities including atypical squamous cells of undetermined sig...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000369-44 Sponsor Protocol Number: 111375 Start Date*: 2009-03-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first v...
    Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020227-48 Sponsor Protocol Number: 113618 Start Date*: 2011-01-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open-label, multi-centre immunization study to evaluate the safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1...
    Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18....
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000090-15 Sponsor Protocol Number: 213749 Start Date*: 2022-12-19
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 1/2 randomized, observer-blinded, multi-country study to evaluate safety and immunogenicity of investigational adjuvanted human papillomavirus vaccine in females (16 to 26 years of age)
    Medical condition: Active immunisation for the prevention of human papillomavirus infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10071146 Human papilloma virus immunisation PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) LT (Completed) FR (Completed) BG (Completed) EE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 21:55:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA